{"product_id":"tumor-suppressing-viruses-genes-and-drugs-innovative-cancer-therapy-approaches-hardback-9780124762497","title":"Tumor Suppressing Viruses, Genes, and Drugs; Innovative Cancer Therapy Approaches (Hardback) 9780124762497","description":"\u003cfont face=\"Georgia\"\u003e\r\n\u003cp\u003e\u003cfont size=\"6\"\u003eTumor Suppressing Viruses, Genes, and Drugs\u003c\/font\u003e\u003cbr\u003e\r\n\u003cfont size=\"5\"\u003eInnovative Cancer Therapy Approaches\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\r\n\r\n\r\n\u003cp\u003e\u003cfont size=\"4\"\u003eHiroshi Maruta (Edited by)\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003e9780124762497\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003eHardback, published 3 December 2001\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003e425 pages\u003cbr\u003e22.9 x 15.2 x 2.7 cm, 0.72 kg\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\r\n\r\n\u003cp align=\"justify\"\u003e\u003cem\u003e\u003cfont size=\"3\"\u003e\"...a brave attempt to encompass a broad, exciting and developing field.\" \u003cb\u003e--MICROBIOLOGY TODAY (2003)\u003c\/b\u003e\u003c\/font\u003e\u003c\/em\u003e\u003c\/p\u003e\r\n\r\n\u003cp align=\"justify\"\u003e\u003cstrong\u003e\u003cfont size=\"3\"\u003e\u003cb\u003eTumor Suppressing Viruses, Genes, and Drugs\u003c\/b\u003e profiles the new generation of cancer treatments now in development. The book examines the innovative new approaches of viral, gene, and signal therapies that promise to replace or enhance conventional methods such as surgery, radiation, and chemotherapy. The timely information presented by this book should be of interest to anyone concerned with advancing cancer treatment beyond current medical practices.\u003c\/font\u003e\u003c\/strong\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003eContributors\u003cbr\u003ePreface\u003cbr\u003e1 Oncolytic Viruses: Virotherapy for Cancer\u003cbr\u003e     I. Introduction\u003cbr\u003e     II. Attributes of Replication-Selective Viruses for Cancer Treatment\u003cbr\u003e     III. Approaches to Optimizing Tumor-Selective Viral Replication\u003cbr\u003e     IV. Adenoviruses\u003cbr\u003e     V. Poliovirus\u003cbr\u003e     VI. Vesicular Stomatitis Virus\u003cbr\u003e     VII. Reovirus\u003cbr\u003e     VIII. Bacteria\u003cbr\u003e     IX. Vaccinia Virus\u003cbr\u003e     X. Herpesvirus\u003cbr\u003e     XI. Clinical Trial Results with Replication-Competent Adenoviruses in Cancer Patients\u003cbr\u003e     XII. Results from Clinical Trials with dl1520 (Onyx-015, or CI-1042)\u003cbr\u003e     XIII. Future Directions: Approaches to Improving the Efficacy of Replication-Selective Viral Agents\u003cbr\u003e     XIV. Summary\u003cbr\u003e     References\u003cbr\u003e2 Reovirus Therapy of Ras-Associated Cancers\u003cbr\u003e     I. Introduction\u003cbr\u003e     II. Reovirus Oncolysis\u003cbr\u003e     III. Concluding Remarks\u003cbr\u003e     References\u003cbr\u003e3 Oncolytic Herpes Simplex Virus (G207) Therapy: From Basic to Clinical\u003cbr\u003e     I. Introduction\u003cbr\u003e     II. Preclinical Studies of G207\u003cbr\u003e     III. G207 Clinical Trial\u003cbr\u003e     IV. Conclusions\u003cbr\u003e     References\u003cbr\u003e4 p53 and Its Targets\u003cbr\u003e     I. Introduction\u003cbr\u003e     II. Activation of p53\u003cbr\u003e     III. Downstream Mediators of p53\u003cbr\u003e     References\u003cbr\u003e5 Prospects for Tumor Suppressor Gene Therapy: RB as an Example\u003cbr\u003e     I. Introduction\u003cbr\u003e     II. Functions of RB\u003cbr\u003e     III. Successes with RB Gene Therapy \u003cbr\u003e     IV. Perspectives\u003cbr\u003e     References\u003cbr\u003e6 CDK Inhibitors: Genes and Drugs\u003cbr\u003e     I. Introduction\u003cbr\u003e     II. G1 Regulation \u003cbr\u003e     III. p16INK4a and the Rb Pathway\u003cbr\u003e     IV. p19ARF and p53 Pathway\u003cbr\u003e     V. p27 and Human Cancer\u003cbr\u003e     VI. Conclusions and Future Perspectives\u003cbr\u003e     References\u003cbr\u003e7 CDK Inhibitors: Small Molecular Weight Compounds\u003cbr\u003e     I. Introduction\u003cbr\u003e     II. Cyclin-Dependent Kinases, the Cell Cycle, and Cancer\u003cbr\u003e     III. Cyclin-Dependent Kinase Inhibitors, a Large Variety of Structures\u003cbr\u003e     IV. Cyclin-Dependent Kinase Inhibitors, All Competing with ATP\u003cbr\u003e     V. Cyclin-Dependent Kinase Inhibitors, the Selectivity Problem\u003cbr\u003e     VI. Cyclin-Dependent Kinase Inhibitors, Cellular Effects\u003cbr\u003e     VII. Cyclin-Dependent Kinase Inhibitors, Antitumor Activity\u003cbr\u003e     VIII. Conclusion\u003cbr\u003e     References\u003cbr\u003e8 NF1 and Other RAS-Binding Peptides\u003cbr\u003e     I. RAS Molecules: Normal versus Oncogenic Mutants \u003cbr\u003e     II. Super GAP?\u003cbr\u003e     III. RAS-Binding Fragment of NF1\u003cbr\u003e     IV. c-RAF-1\u003cbr\u003e     V. PI-3 Kinase\u003cbr\u003e     VI. Ral GDS \u003cbr\u003e     References\u003cbr\u003e9 Cytoskeletal Tumor Suppressor Genes\u003cbr\u003e     I. Introduction (Historical Background)\u003cbr\u003e     II. Type I Cytoskeletal Tumor Suppressors\u003cbr\u003e     III. Type II Cytoskeletal Tumor Suppressors\u003cbr\u003e     References\u003cbr\u003e10 TGF-? Signaling and Carcinogenesis\u003cbr\u003e     I. Introduction\u003cbr\u003e     II. Dual Role of TGF-? in Carcinogenesis\u003cbr\u003e     III. TGF-? Superfamily Signaling\u003cbr\u003e     IV. Perturbation of TGF-? Signaling in Cancer Cells\u003cbr\u003e     V. Perspectives\u003cbr\u003e     References\u003cbr\u003e11 DAN Gene\u003cbr\u003e     I. Introduction\u003cbr\u003e     II. Cloning of DAN cDNA\u003cbr\u003e     III. Transfection of DAN\u003cbr\u003e     IV. Role of DAN in Neuroblastomas\u003cbr\u003e     V. Structural Features of the DAN Protein\u003cbr\u003e     VI. Genomic Structure of DAN\u003cbr\u003e     VII. DAN Family\u003cbr\u003e     References\u003cbr\u003e12 Design of Hammerhead Ribozymes and Allosterically Controllable Maxizymes for Cancer Gene Therapy\u003cbr\u003e     I. Introduction\u003cbr\u003e     II. Ribozyme Expression System in Cells\u003cbr\u003e     III. Design of the tRNAVal-Driven Ribozyme That Is Transcribed by pol III\u003cbr\u003e     IV. Design of Allosterically Controlled Maxizymes\u003cbr\u003e     V. Conclusion\u003cbr\u003e     References\u003cbr\u003e13 Inhibitors of Angiogenesis\u003cbr\u003e     I. Introduction—Angiogenesis\u003cbr\u003e     II. Angiogenesis Inhibitors\u003cbr\u003e     III. Future Directions\u003cbr\u003e     References\u003cbr\u003e14 Geranylgeranylated RhoB Mediates the Apoptotic and Antineoplastic Effects of Farnesyltransferase Inhibitors: New Insights into Cancer Cell Suicide\u003cbr\u003e     I. Introduction \u003cbr\u003e     II. Do Farnesyltransferase Inhibitors Target a Unique Aspect of Neoplastic Pathophysiology?\u003cbr\u003e     III. Ras Is Not a Crucial Target of Farnesyltransferase Inhibitors\u003cbr\u003e     IV. RhoB Is a Crucial Target of Farnesyltransferase Inhibitors\u003cbr\u003e     V. Farnesyltransferase Inhibitors Act through a Gain of Function Mechanism Involving RhoB-GG\u003cbr\u003e     VI. RhoB-GG Is Required to Mediate Apoptosis by Farnesyltransferase Inhibitors\u003cbr\u003e     VII. RhoB-GG and the Antiangiogenic Properties of Farnesyltransferase Inhibitors\u003cbr\u003e     VIII. Clinical Implications\u003cbr\u003e     IX. Summary\u003cbr\u003e     References\u003cbr\u003e15 RAS Binding Compounds\u003cbr\u003e     I. Introduction\u003cbr\u003e     II. Ras Cycle and Ras–Raf Signaling Pathway\u003cbr\u003e     III. The Structure of Ras Proteins\u003cbr\u003e     IV. Drug Target Sites of Ras\u003cbr\u003e     V. Conclusions and Outlook\u003cbr\u003e     References\u003cbr\u003e16 Actin-Binding Drugs: MKT-077 and Chaetoglobosin K (CK)\u003cbr\u003e     I. Introduction\u003cbr\u003e     II. MKT-077: F-Actin Bundler\u003cbr\u003e     III. Chaetoglobosin K: F-Actin Capper\u003cbr\u003e     References\u003cbr\u003e17 Tyr Kinase Inhibitors as Potential Anticancer Agents: EGF Receptor and ABL Kinases\u003cbr\u003e     I. Introduction\u003cbr\u003e     II. Tyr Kinase Inhibitors\u003cbr\u003e     III. Chronic Myelogenous Leukemia\u003cbr\u003e     IV. Epidermal Growth Factor Receptor\u003cbr\u003e     V. Antagonists of the Epidermal Growth Factor Receptor Extracellular Domain\u003cbr\u003e     VI. Chemical Inhibitors of the Kinase Domain of the Epidermal Growth Factor Receptor\u003cbr\u003e     VII. Epidermal Growth Factor Receptor Antagonists or Inhibitors Act Synergistically to Kill Tumor Cells\u003cbr\u003e     VIII. The Effects of Abl Inhibitors on Leukemia\u003cbr\u003e     References\u003cbr\u003e18 Antagonists of Rho Family GTPases: Blocking PAKs, ACKs, and Rock\u003cbr\u003e     I. Rho Family GTPases (Rho, Rac, and CDC42)\u003cbr\u003e     II. Blocking PAKs\u003cbr\u003e     III. Blocking CDC42 Pathways (ACKs and N-WASP)\u003cbr\u003e     IV. Blocking Rho Pathways\u003cbr\u003e     V. Rac-Specific Inhibitors?\u003cbr\u003e     References\u003cbr\u003e19 Integrin Antagonists as Cancer Therapeutics\u003cbr\u003e     I. Introduction\u003cbr\u003e     II. Signaling Pathways Activated by Integrins\u003cbr\u003e     InII. Role of Integrins in Neoplastic Transformatio\u003cbr\u003e     IV. Role of Integrins in Tumor-Induced Angiogenesis\u003cbr\u003e     V. Integrin Antagonists as Antiangiogenesis Agents\u003cbr\u003e     VI. Conclusions and Future Perspectives\u003cbr\u003e     References\u003cbr\u003e20 Functional Rescue of Mutant p53 as a Strategy to Combat Cancer\u003cbr\u003e     I. Introduction \u003cbr\u003e     II. Multiple Pathways of p53-Induced Apoptosis\u003cbr\u003e     III. Regulation of p53 Activity\u003cbr\u003e     IV. Approaches toward Reactivation of Mutant p53\u003cbr\u003e     V. Implications for Tumor Therapy and Future Perspectives\u003cbr\u003e     References\u003cbr\u003eIndex\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003eSubject Areas: Virology [\u003ca title=\"See our other books on Virology\" href=\"https:\/\/freshlyprintedbooks.co.uk\/search?q=%22Virology%20%5Bnon-medical%5D%20%5BPSGL%5D%22\"\u003enon-medical PSGL\u003c\/a\u003e], Oncology [\u003ca title=\"See our other books on Oncology\" href=\"https:\/\/freshlyprintedbooks.co.uk\/search?q=%22Oncology%20%5BMJCL%5D%22\"\u003eMJCL\u003c\/a\u003e]\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\r\n\u003c\/font\u003e","brand":"Freshly Printed Books","offers":[{"title":"Default Title","offer_id":46649422905624,"sku":"9780124762497","price":83.69,"currency_code":"GBP","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0730\/2037\/5320\/products\/9780124762497.jpg?v=1694100894","url":"https:\/\/freshlyprintedbooks.co.uk\/products\/tumor-suppressing-viruses-genes-and-drugs-innovative-cancer-therapy-approaches-hardback-9780124762497","provider":"Freshly Printed Books","version":"1.0","type":"link"}